Abstract
The concept to use antibodies recognizing antigens associated with tumours for imaging and therapy, has gained great interest with the development of monoclonal antibodies. Originally one believed that hybridoma technology could give monoclonal antibodies reacting specifically with a particular tumour. Today the experience shows that most of monoclonal antibodies produced are tumour associated. This suggests that some cross reactions with normal tissues exist.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660–672.
Powe J, Herlyn D, Munz D et al. Radi oi mmunodetect i on of human tumour xenografts by monoclonal antibodies correlates with antibody density and affinity. Immunoscintigraphy, New York Gordon and Breach Science Publications, 1985; 139–156.
Keenan A M, Colcher D, Larson D M, Schlom J. Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B 72–3. J Nucl Med 1984; 25: 1197–1203.
Epenetos A, Shepherd J, Britton K, and al. Radioimmuno- diagnosis of ovarian cancer using 1–123 labelled tumour associated monoclonal antibodies. Cancer Detect and Prev 1984; 7: 45–49.
Munz D L, Alavi A, Koprowski H, Herlyn D. Improved Radioimmunoimaging of human tumour xenografts by a mixture of monoclonal antibody F(ab’)2 fragments. J Nucl Med 1986; 27: 1739–1745.
Chatal J F, Saccavini J C, Fumoleau P et al. Immunoscinti-graphy of colon carcinoma J Nucl Med 1984; 25: 307–314.
Moyle W R, Chenfang L, Corson R L et al. Quantitative explanation for increased affinity shown by mixtures of monoclonal antibodies. Mol Immunol 1983; 20: 439–452.
Pressman D. Radiolabeled antibodies. Ann N Y Acad Sci 1957; 69: 644–650.
Moshakis V Mc Lielhinney AJ, Raghaven D et al. Monoclonal antibodies to detect human tumours: an experimental approach J Clin Pathos 1981; 34: 314–319.
Larson S, Brown J P, Wright P W et al. Imaging of melanoma with I 131 monoclonal antibodies. J Nucl Med 1983; 24: 123–129
Parham P, On the fragmentation of monoclonal IgGl, IgG2a and IgG2b from BALB/c mice. J of Immunol 1983; 2895–2902.
Ballou B, Reiland J, Levine G et al. Tumour localisation using F(ab’)2 from a monoclonal IgM antibody: Pharmacokinetics. J Nucl Med 1985; 26: 283–292.
Ishikawa E, Imagawa M, Hashida S et al. Enzyme labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. J of Immunoass. 1983; 4 (3): 209–327.
Buchegger F, Hasekll Ch M, Schreger M et al. Radiolabeled fragment of monoclonal antibodies against carcinoembryonic antigen for localisation of human carcinoma grafted into nude mide. J Exp Med 1983; 158: 413–427.
Andrew S M, Pimm M, Perkins A C, Baldwin R W. Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab’)2 and Fab fragments in mice with colon carcinoma xenografts. Eur J Nucl Med 1986; 12: 168–175.
Whal R L, Parker C W, Philpott G W. Improved Radioimaging and tumour localisation with monoclonal F(ab’)2. J Nucl Med 1983; 24: 316–325.
Hunter W M, Greenwood F C. Preparation of 1-131, labeled human growth hormones at high specific activity. Nature 1962; 194: 495–496.
Fraker P J, Speck J C. Protein and cell membrane iodina- tions with a sparingly soluble chloroamide 1,3,4,6 tetra- chloro-3, 6 diphenyl glycoluri1. Biochem. and Biophys Res Comm 1978; 80: 849–857.
Marchalonis J J. an ezymic method for the tracer iodina- tion of immunoglobulins and other proteins. Biochem J 1969; 113: 299–305.
Hnatowich D S, Layne W W, Chilos R L et al. The preparation and labeling of DTPA-coupled albumin Int J Appl Rad Isot 1982; 33: 327–332.
Meares C F, Mc Call M J, Reardan D T et al. Conjugation of antibodies with bifunctional chelating agents isothio-cyanate and Bromoacetamide Reagents. Methods of analysis an subsequent addition of metal ions. Analyt Biochem 1984; 142 (I): 68–78.
Goodwin D A, Meares C F, Mc Tigue M et al Metal decomposition rates of In 111 DTPA and EDTA conjugates of monoclonal antibodies in vivo. Nucl Med Comm 1986; 7: 831–838.
Hnatowich D J, Griffin T W, Koscinczyk C et al. Pharmacokinetics of an In 111 labeled monoclonal antibody in cancer patients. J Nucl Med 1985; 26: 849–858.
Reardan D T, Meares C F, Goodwin D A et al. Antibodies against metal chelates. Nature 1985; 316: 265–267.
Hnatowich D J, Altering the in-vivo behaviour of radio-labeled antibodies through the use of avidin-biotin. World federation Congress of Nuclear Medecine and Biology. 2–7 Novembre 1986 Buenos-Aires.
Lindmo T, Boven E, Cuttitta F et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J of Immunol Meth 1984; 72: 77–88.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
Saccavini, J.C., Chatal, J.F., Kremer, M. (1987). Design and Development of Radiopharmaceuticals Based on Monoclonal Antibodies. In: Kristensen, K., Nørbygaard, E. (eds) Safety and Efficacy of Radiopharmaceuticals 1987. Developments in Nuclear Medicine, vol 14. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3375-0_2
Download citation
DOI: https://doi.org/10.1007/978-94-009-3375-0_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-8016-3
Online ISBN: 978-94-009-3375-0
eBook Packages: Springer Book Archive